- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Dutch Fight Over H5N1 Export Rules Moves to Court of Appeal
4 November 2013 2:15 pm
AMSTERDAM—The legal battle between Ron Fouchier and the Dutch government over the publication of controversial research on the H5N1 avian influenza virus is set to continue. On Friday, Fouchier’s employer, Erasmus MC in Rotterdam, formally appealed a ruling by a Dutch court that the government was within its rights when it put limits on Fouchier’s freedom to publish his work with the virus.
The appeal is the latest twist in the long-running saga of two papers showing how a few mutations can make H5N1 more transmissible among mammals. Fouchier’s paper was published in Science in June 2012—but before submitting the manuscript, Fouchier had to obtain a so-called export license because the government deemed the work of potential interest by bioterrorists. Fouchier did so under protest, and Erasmus MC went to court over the issue. On 20 September, the district court in Haarlem ruled that the government correctly interpreted a 2009 European regulation that seeks to prevent the proliferation of nuclear, chemical and biological weapons.
Fouchier—who has since applied for a second export license, for an as-yet unpublished H5N1 paper—says he’s satisfied that Erasmus MC wants to continue the fight, which will now move to the Court of Appeal in Amsterdam. He says the Dutch export rules are an attack on academic freedom; others have pointed out that the court ruling also raises a number of new questions about how the sensitive studies are regulated.
Meanwhile, the European Society for Virology (ESV) has sided with Fouchier on the issue. In a letter to José Manuel Barroso, the president of the European Commission, ESV President Giorgio Palù warns that “this Dutch ruling may have far-stretching implications for research and public and animal health within all EU Member States.”
Requiring export licenses for H5N1 and the many dozens of other pathogens covered by the E.U. regulation is not only at odds with the principle of academic freedom but may also cause delays in the dissemination of scientific information on infectious diseases and may conflict with international agreements, such as the International Health Regulations, Palù writes. The letter says the issue should be debated at the European level.
ESV is the first scientific society to take sides in the issue; Fouchier says he has heard that other organizations are now preparing to speak out as well. The Royal Netherlands Academy of Arts and Sciences has not taken a position; it is awaiting a report on dual-use regulation by an independent panel, requested by the Dutch government, which a spokesperson says will be presented later this month.